<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-114062</identifier>
<setSpec>0211-5735</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Leucopenia and neutropenia rapidly evolving induced by olanzapine</dc:title>
<dc:description xml:lang="en">Some antipsychotics drugs are associated with blood dyscrasias. The psychotropic medication most frequently associated with agranulocytosis is clozapine (0,5-2% of patients). Olanzapine is a second-generation antipsychotic with a chemical structure similar to clozapine, with a risk of neutropenic reactions of 1/10.000 treated patients. We report the case of a 32-yearold man without medical or psychiatric records, who was admitted due to a first psychotic episode. In a blood test previous to hospitalization, complete blood cell count was normal (white blood cell count 8,92x103/ul, neutrophilic count 6,99x103/ul). Three days after initiation of olanzapine 20mg/day, WBC count had fallen to 2,46x103/ul (neutrophilic count 0,64x103/ul). After replacing olanzapine, initially for risperidone and later for intramuscular zuclopentixol, WBC count gradually increased. On the twelfth day of olanzapine withdrawal, complete blood cell count had normalized (WBC count 5,73x103/ul) (AU)</dc:description>
<dc:creator>Llobet Farré, Maria</dc:creator>
<dc:creator>Bulbena Vilarrasa, Antoni</dc:creator>
<dc:creator>León Caballero, Jordi</dc:creator>
<dc:creator>González Contreras, Luis</dc:creator>
<dc:creator>Ramos Perdigues, Sonia</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Algunos antipsicóticos se asocian a discrasias sanguíneas. El psicofármaco que más produce agranulocitosis es la clozapina (0,5-2% de los pacientes). La olanzapina es un antipsicótico de segunda generación con estructura química similar a la clozapina que tiene un riesgo de leucopenia/neutropenia de 1/10.000 pacientes tratados. Presentamos el caso de un paciente de 32 años sin antecedentes somáticos ni psiquiátricos, hospitalizado por un primer episodio psicótico. En la analítica previa al ingreso no había alteraciones en el hemograma (leucocitos totales 8,92x103/ul, neutrófilos totales 6,99x103/ul). A los tres días de haber iniciado tratamiento con olanzapina 20mg/día el recuento leucocitario había disminuido a 2,46x103/ul (neutrófilos totales 0,64x103/ ul). Tras sustituir la olanzapina, inicialmente por risperidona y posteriormente por zuclopentixol intramuscular, el recuento leucocitario fue aumentando progresivamente. A los doce días de la retirada, el hemograma se había normalizado (leucocitos totales 5,73x103/ul) (AU)</dc:description>
<dc:source>Rev. Asoc. Esp. Neuropsiquiatr;33(119): 603-606, jul.-sept. 2013.</dc:source>
<dc:identifier>ibc-114062</dc:identifier>
<dc:title xml:lang="es">Leucopenia y neutropenia de rápida evolución inducidas por olanzapina</dc:title>
<dc:subject>^d8146^s22012</dc:subject>
<dc:subject>^d12036^s22045</dc:subject>
<dc:subject>^d9691^s22012</dc:subject>
<dc:subject>^d6560^s22021</dc:subject>
<dc:subject>^d9691^s22036</dc:subject>
<dc:subject>^d9691^s22016</dc:subject>
<dc:subject>^d14542^s22073</dc:subject>
<dc:subject>^d8146^s22036</dc:subject>
<dc:subject>^d14542^s22020</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23481^s22066</dc:subject>
<dc:subject>^d23481^s22045</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d23481^s22074</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d384^s22016</dc:subject>
<dc:subject>^d86^s22073</dc:subject>
<dc:subject>^d384^s22012</dc:subject>
<dc:subject>^d32618^s22073</dc:subject>
<dc:subject>^d12036^s22066</dc:subject>
<dc:type>article</dc:type>
<dc:date>201309</dc:date>
</metadata>
</record>
</ibecs-document>
